DGAP-Adhoc: RHÖN-KLINIKUM AG signs memorandum of understanding regarding establishment of joint company with Swiss telemedicine provider Medgate
DGAP-Ad-hoc: RHÖN-KLINIKUM AG / Key word(s): Letter of Intent
RHÖN-KLINIKUM AG signs memorandum of understanding regarding establishment of joint company with Swiss telemedicine provider Medgate
10-Jan-2019 / 09:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Bad Neustadt a. d. Saale | 10 January 2019. RHÖN-KLINIKUM AG (WKN 704230/ ISIN DE0007042301) today signed a memorandum of understanding with Swiss telemedicine provider Medgate. The object of the memorandum of understanding is the joint provision of telemedicine and digital medical services in Germany. For this purpose, RHÖN-KLINIKUM AG and Medgate International AG plan to establish a joint company ("Medgate Germany") located in Germany in which RHÖN-KLINIKUM AG has a 51 per cent stake and Medgate has a 49 per cent stake.
Medgate Germany shall, within the German regulatory framework, provide patients with urgent or general medical questions with advice and treatment via telephone, internet or video conference. With Medgate Germany, RHÖN-KLINIKUM AG and Medgate strive for market leadership in the field telemedicine and digital medical services in Germany. The establishment of Medgate Germany requires the prior consent of the supervisory board of RHÖN-KLINIKUM AG and of the administrative board of Medgate International AG. The existence of further, e.g. regulatory, clearance requirements is still to be examined.
In addition to the establishment of Medgate Germany, RHÖN-KLINIKUM AG considers participations in Medgate Holding AG and/or one of its subsidiaries or the establishment of an additional joint company with Medgate in which the intellectual property and know how required for the services of Medgate Germany will be bundled and developed further and the necessary IT solution will be realized.
Contact Corporate Communications:
RHÖN-KLINIKUM AG | Head of Corporate Communications and Marketing
Elke Pfeifer
T. +49 9771 65-1327 | [email protected]
Contact Investor Relations:
RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt
T. +49 9771 65-1536 | [email protected]
RHÖN-KLINIKUM AG
Schlossplatz 1
Bad Neustadt a. d. Saale
10-Jan-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
RHÖN-KLINIKUM AG |
|
Salzburger Leite 1 |
|
97616 Bad Neustadt a.d.Saale |
|
Germany |
Phone: |
+49 (0)9771 - 65-0 |
Fax: |
+49 (0)9771 - 97 467 |
E-mail: |
[email protected] |
Internet: |
www.rhoen-klinikum-ag.com |
ISIN: |
DE0007042301 |
WKN: |
704230 |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
|
End of Announcement |
DGAP News Service |
764895 10-Jan-2019 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
1.211,08 |
1.232,91 |
1.303,90 |
1.360,16 |
1.402,01 |
1.446,09 |
1.463,98 |
EBITDA1,2 |
97,82 |
125,54 |
125,33 |
80,23 |
101,16 |
105,65 |
105,88 |
EBITDA-Marge3 |
8,08 |
10,18 |
9,61 |
5,90 |
7,22 |
7,31 |
|
EBIT1,4 |
38,70 |
64,94 |
56,80 |
10,60 |
30,52 |
36,11 |
40,40 |
EBIT-Marge5 |
3,20 |
5,27 |
4,36 |
0,78 |
2,18 |
2,50 |
2,76 |
Jahresüberschuss1 |
36,74 |
51,19 |
44,48 |
2,46 |
30,23 |
26,94 |
40,17 |
Netto-Marge6 |
3,03 |
4,15 |
3,41 |
0,18 |
2,16 |
1,86 |
2,74 |
Cashflow1,7 |
80,30 |
49,50 |
47,30 |
113,30 |
97,50 |
41,30 |
109,00 |
Ergebnis je Aktie8 |
0,53 |
0,73 |
0,65 |
0,02 |
0,42 |
0,38 |
0,58 |
Dividende8 |
0,22 |
0,29 |
0,00 |
0,00 |
0,00 |
0,15 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Rhön-Klinikum |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
704230 |
10,900 |
Halten |
729,89 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
18,17 |
28,00 |
0,64 |
18,63 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,58 |
6,70 |
0,50 |
6,30 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,15 |
0,00 |
0,00 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
0,87% |
-2,85% |
9,00% |
-16,15% |
|
|